These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 31101455)

  • 1. Functional CD3
    Lv S; Wang S; Qiao G; Wang X; Zhou X; Yan F; Li Y; Wang S; Morse MA; Hobeika A; Ren J; Lyerly HK
    Clin Breast Cancer; 2019 Oct; 19(5):e617-e623. PubMed ID: 31101455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
    Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
    Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast.
    Ubago JM; Blanco LZ; Shen T; Siziopikou KP
    Am J Clin Pathol; 2019 Jul; 152(2):169-176. PubMed ID: 30984969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immune microenvironment of breast ductal carcinoma in situ.
    Thompson E; Taube JM; Elwood H; Sharma R; Meeker A; Warzecha HN; Argani P; Cimino-Mathews A; Emens LA
    Mod Pathol; 2016 Mar; 29(3):249-58. PubMed ID: 26769139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer.
    Hou Y; Nitta H; Wei L; Banks PM; Lustberg M; Wesolowski R; Ramaswamy B; Parwani AV; Li Z
    Breast J; 2018 Nov; 24(6):911-919. PubMed ID: 30230111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune parameters associated with survival in metaplastic breast cancer.
    Chao X; Liu L; Sun P; Yang X; Li M; Luo R; Huang Y; He J; Yun J
    Breast Cancer Res; 2020 Aug; 22(1):92. PubMed ID: 32811533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher densities of tumour-infiltrating lymphocytes and CD4
    Thike AA; Chen X; Koh VCY; Binte Md Nasir ND; Yeong JPS; Bay BH; Tan PH
    Histopathology; 2020 May; 76(6):852-864. PubMed ID: 31883279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer.
    Okabe M; Toh U; Iwakuma N; Saku S; Akashi M; Kimitsuki Y; Seki N; Kawahara A; Ogo E; Itoh K; Akagi Y
    Cancer Sci; 2017 Jan; 108(1):81-90. PubMed ID: 27801993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
    Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
    Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
    Kassardjian A; Shintaku PI; Moatamed NA
    PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of CXCL10 in the progression of in situ to invasive carcinoma of the breast.
    Kim M; Choi HY; Woo JW; Chung YR; Park SY
    Sci Rep; 2021 Sep; 11(1):18007. PubMed ID: 34504204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
    Fernandez SV; MacFarlane AW; Jillab M; Arisi MF; Yearley J; Annamalai L; Gong Y; Cai KQ; Alpaugh RK; Cristofanilli M; Campbell KS
    Breast Cancer Res; 2020 Dec; 22(1):134. PubMed ID: 33267869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
    Flores-Martín JF; Perea F; Exposito-Ruiz M; Carretero FJ; Rodriguez T; Villamediana M; Ruiz-Cabello F; Garrido F; Cózar-Olmo JM; Aptsiauri N
    Ann Surg Oncol; 2019 Aug; 26(8):2631-2639. PubMed ID: 31011905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
    Toss MS; Abidi A; Lesche D; Joseph C; Mahale S; Saunders H; Kader T; Miligy IM; Green AR; Gorringe KL; Rakha EA
    Br J Cancer; 2020 May; 122(10):1496-1506. PubMed ID: 32203210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8
    Eissa IR; Mukoyama N; Abdelmoneim M; Naoe Y; Matsumura S; Bustos-Villalobos I; Ichinose T; Miyajima N; Morimoto D; Tanaka M; Fujimoto Y; Sone M; Kodera Y; Kasuya H
    Int J Cancer; 2021 Jul; 149(1):214-227. PubMed ID: 33687756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.
    Gabrielson A; Wu Y; Wang H; Jiang J; Kallakury B; Gatalica Z; Reddy S; Kleiner D; Fishbein T; Johnson L; Island E; Satoskar R; Banovac F; Jha R; Kachhela J; Feng P; Zhang T; Tesfaye A; Prins P; Loffredo C; Marshall J; Weiner L; Atkins M; He AR
    Cancer Immunol Res; 2016 May; 4(5):419-30. PubMed ID: 26968206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.
    Wesolowski R; Stiff A; Quiroga D; McQuinn C; Li Z; Nitta H; Savardekar H; Benner B; Ramaswamy B; Lustberg M; Layman RM; Macrae E; Kassem M; Williams N; Sardesai S; VanDeusen J; Stover D; Cherian M; Mace TA; Yu L; Duggan M; Carson WE
    BMC Cancer; 2020 May; 20(1):445. PubMed ID: 32429929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ductal carcinoma in situ of the breast: immune cell composition according to subtype.
    Agahozo MC; van Bockstal MR; Groenendijk FH; van den Bosch TPP; Westenend PJ; van Deurzen CHM
    Mod Pathol; 2020 Feb; 33(2):196-205. PubMed ID: 31375764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinoblastoma Is Characterized by a Cold, CD8+ Cell Poor, PD-L1- Microenvironment, Which Turns Into Hot, CD8+ Cell Rich, PD-L1+ After Chemotherapy.
    Miracco C; Toti P; Gelmi MC; Aversa S; Baldino G; Galluzzi P; De Francesco S; Petrelli F; Sorrentino E; Belmonte G; Galimberti D; Bracco S; Hadjistilianou T
    Invest Ophthalmol Vis Sci; 2021 Feb; 62(2):6. PubMed ID: 33538768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.